Yu-Han Hung

机构：Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Bristol-Myers Squibb (United States), Centre de Recherche en Cancérologie de Lyon, Bristol-Myers Squibb (Sweden), Onco Lille, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers · ORCID：0000-0002-3278-3201

发表论文 64 篇 · 总被引 630 次 · h-index 15

代表论文

• miR-29 is an important driver of aging-related phenotypes (2024 · Communications Biology · 被引 31)
• Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets (2025 · Cancer Discovery · 被引 15)
• Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 (2026 · Journal of Clinical Oncology · 被引 5)
• Abstract CT015: Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T (2026 · Cancer Research · 被引 1)
• LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial (2025 · Clinical Cancer Research · 被引 1)
• Biomarkers of nivolumab benefit in resectable non-small cell lung cancer (2026 · Nature)